Evidence map›Paper›PMID 31491907›Full record

ArticleMarine drugs2019

First Results from a Screening of 300 Naturally Occurring Compounds: 4,6-dibromo-2-(2',4'-dibromophenoxy)phenol, 4,5,6-tribromo-2-(2',4'-dibromophenoxy)phenol, and 5-epi-nakijinone Q as Substances with the Potential for Anticancer Therapy.

Saskia Mayer, Marie Prechtl, Pia Liebfried, Ron-Patrick Cadeddu, Fabian Stuhldreier, Matthias Kohl, Folker Wenzel, Björn Stork, Sebastian Wesselborg, Peter Proksch and 3 more

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Saskia MayerFaculty Medical and Life Sciences, Campus Villingen-Schwenningen, Hochschule Furtwangen University, 78120 Furtwangen, Germany. Mayer.Saskia@gmx.net.
Marie PrechtlFaculty Medical and Life Sciences, Campus Villingen-Schwenningen, Hochschule Furtwangen University, 78120 Furtwangen, Germany. marie.prechtl97@gmx.de.
Pia LiebfriedDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Pia.Liebfried@ucb.com.
Ron-Patrick CadedduDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Ron-Patrick.Cadeddu@med.uni-duesseldorf.de.ORCID 0000-0003-0484-5660
Fabian StuhldreierInstitute for Molecular Medicine I, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Fabian.Stuhldreier@uni-duesseldorf.de.ORCID 0000-0002-0578-7530
Matthias KohlFaculty Medical and Life Sciences, Campus Villingen-Schwenningen, Hochschule Furtwangen University, 78120 Furtwangen, Germany. kohl@hs-furtwangen.de.ORCID 0000-0001-9514-8910
Folker WenzelFaculty Medical and Life Sciences, Campus Villingen-Schwenningen, Hochschule Furtwangen University, 78120 Furtwangen, Germany. Folker.Wenzel@hs-furtwangen.de.
Björn StorkInstitute for Molecular Medicine I, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. bjoern.stork@uni-duesseldorf.de.ORCID 0000-0002-4167-7806
Sebastian WesselborgInstitute for Molecular Medicine I, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. sebastian.wesselborg@uni-duesseldorf.de.
Peter ProkschInstitute of Pharmaceutical Biology and Biotechnology, Heinrich Heine University, 40225 Düsseldorf, Germany. Peter.Proksch@hhu.de.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Germing@med.uni-duesseldorf.de.
Rainer HaasDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Haas@med.uni-duesseldorf.de.
Paul JägerDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. PaulSebastian.Jaeger@med.uni-duesseldorf.de.ORCID 0000-0001-9250-2064
Düsseldorf University Hospital · DEFurtwangen University · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a variety of antineoplastic drugs that are based on natural compounds from ecological niches with high evolutionary pressure. We used two cell lines (Jurkat J16 and Ramos) in a screening to assess 300 different naturally occurring compounds with regard to their antineoplastic activity. The results of the compounds 4,6-dibromo-2-(2',4'-dibromophenoxy)phenol (P01F03), 4,5,6-tribromo-2-(2',4'-dibromophenoxy)phenol (P01F08), and 5-epi-nakijinone Q (P03F03) prompted us to perform further research. Using viability and apoptosis assays on the cell lines of primary human leukemic and normal hematopoietic cells, we found that P01F08 induced apoptosis in the cell lines at IC50 values between 1.61 and 2.95 μM after 72 h. IC50 values of peripheral blood mononuclear cells (PBMNCs) from healthy donors were higher, demonstrating that the cytotoxicity in the cell lines reached 50%, while normal PBMNCs were hardly affected. The colony-forming unit assay showed that the hematopoietic progenitor cells were not significantly affected in their growth by P01F08 at a concentration of 3 μM. P01F08 showed a 3.2-fold lower IC50 value in primary leukemic cells [acute myeloid leukemia (AML)] compared to the PBMNC of healthy donors. We could confirm the antineoplastic effect of 5-epi-nakijinone Q (P03F03) on the cell lines via the induction of apoptosis but noted a similarly strong cytotoxic effect on normal PBMNCs.

Indexed as

AdultAgedAntineoplastic AgentsApoptosisCell Line, TumorFemaleHematopoietic Stem CellsHL-60 CellsHumansJurkat CellsLeukemia, Myeloid, AcuteLeukocytes, MononuclearMaleMiddle AgedPhenolTHP-1 CellsAntineoplastic AgentsPhenolacute myeloid leukemiaapoptosisbioactive natural productscytotoxic activitydrug leadsmarine sponge derived natural productsperipheral blood mononuclear cellspolybrominated diphenyl ethersprimary leukemic cellssesquiterpene aminoquinone

Identifiers

PMID31491907
PMCPMC6780284
OpenAlexW2971474053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.